Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their
growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating
patients who have recurrent or refractory advanced T-cell leukemia.
Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every
week for up to six courses. Patients are not required to be hospitalized for the
administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777
twice a week for 6 weeks.